soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Semaglutide and Cardiovascular Outcomes in

The study provided mechanistic evidence supporting the bihormonal deficiency model of type 1 diabetes, demonstrating that addressing amylin deficiency in addition to insulin deficiency provides superior glycemic control

Some insurers previously limited GLP-1 coverage for obesity, but Medicare is partially expanding access, though coverage does not reach all who want it

Enhanced Quality of Life: Achieving and maintaining a healthy weight can improve mobility, reduce joint pain, and boost overall well-being and confidence

Accidental acetaminophen overdose results in liver transplant during second trimester of pregnancy: a case report